Incyte (INCY) Could Be 8% Overvalued After Its 22% Three Month Run
Incyte (INCY) stock has drawn investor attention after the latest trading session, with shares closing at US$116.71. That price now sits against a wider performance backdrop across the month and past 3 months.
See our latest analysis for Incyte.
Looking beyond the latest move, Incyte’s share price return of 7.54% over the past month and 22.15% over the past 90 days sits alongside a 1-year total shareholder return of 70.16%, suggesting momentum has been building recently.
If you are comparing Incyte with other opportunities in high growth areas, it could be worth scanning a wider field of AI infrastructure plays using the 52 AI infrastructure stocks.
After that kind of run, Incyte now trades slightly above the average analyst price target and its own estimated fair value range. How wide is the gap between recent enthusiasm and what valuation models suggest is reasonable?
Most Popular Narrative: 8% Overvalued
The most followed narrative currently anchors Incyte’s fair value at about $108.50 per share, which sits below the latest close at $116.71 and frames the recent share price strength as richer than that narrative would imply.
The analysts have a consensus price target of $108.5 for Incyte based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $135.0, and the most bearish reporting a price target of just $71.0.
Want to see what keeps that fair value below today’s share price? The core narrative leans on modest revenue assumptions, thinner profit margins, and a richer future earnings multiple. The exact mix may surprise you.
Result: Fair Value of $108.50 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Incyte still faces two key pressure points: heavy reliance on Jakafi ahead of its patent cliff and ongoing uncertainty around future R&D success and spending.
Find out about the key risks to this Incyte narrative.
Another View on Incyte’s Valuation
The analyst narrative frames Incyte as about 8% overvalued relative to an estimated fair value of $108.50, but the market’s own P/E tells a slightly different story. At 16.3x earnings, the stock trades below the US market at 19.3x and below the US Biotechs industry at 17.4x, yet above a fair ratio of 14.4x that the market could move toward. This leaves investors weighing whether this gap signals valuation risk or a potential premium for quality.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment clearly mixed around Incyte, this is a moment to move quickly, review the full picture, and weigh both sides of the story. To start, see the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Incyte?
If Incyte has your attention, do not stop there. Use the Simply Wall St screener to quickly spot other stocks that fit your style and risk comfort.
- Target income opportunities by reviewing companies with strong payouts and robust coverage through the 9 dividend fortresses.
- Zero in on quality at a reasonable price by scanning the 45 high quality undervalued stocks that blend solid fundamentals with attractive valuations.
- Prioritise resilience by checking the 78 resilient stocks with low risk scores that pair lower risk scores with business profiles designed to handle tougher conditions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com